DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Merck - 2 Singulair - 2 Nicholas England - 1 Nicholas - 1 ” - 1 Jennifer England - 1 Nicholas’s - 1 ” Merck - 1
Top related locs:
U.S Virginia England New York Kirkland East Palestine , Ohio Louisiana Atlanta
Top related orgs:
Merck - 2 FDA - 2 U.S - 1 Teva Pharmaceuticals - 1 U.S . Food - 1 Drug Administration - 1 Big - 1 Corporate America - 1

Search resuls for: "Jan Gilpin"


2 mentions found


☆ A son died, his parents tried to sue. How U.S. courts protect Big Pharma
  + stars: | 2023-06-26 | by ( ) www.reuters.com   time to read: +26 min
His parents soon started exploring a lawsuit against Merck, the developer of the blockbuster asthma and allergy drug, Singulair, along with the manufacturer of the generic version their son took. That meant Merck had written the warning label, with federal approval, on the generic version of Singulair that Nicholas England took. But his parents couldn’t sue Merck, either, because their son had never taken its name-brand version of Singulair. The generic drug manufacturer that made the pills England took, Teva Pharmaceuticals, did not respond to inquiries. Since Merck’s patent on Singulair expired in 2012, major generic drug manufacturers have sold millions of prescriptions under the drug’s scientific name, montelukast.
Persons: Nicholas England, Nicholas, Merck, ”, Jennifer England, Nicholas’s, ” Merck, Organon, “, George W, Bush, Daniel Troy, Troy, Medtronic, Nicholas England’s, Adam Zimmerman, ” Zimmerman, Jay Lefkowitz, Ellis, shouldn’t, Bayer, drugmaker Wyeth, Phenegran, Jan Gilpin’s, mumbling, ” Gilpin, ” “, hadn’t, Singulair, Gilpin, Stephane Bissonnette, suicidality, Dr, Judith Kramer, Duke, Robert England, Robert said, Kim Beck Organizations: Merck, U.S, Teva Pharmaceuticals, Reuters, U.S . Food, Drug Administration, FDA, Big, Corporate America, Corporations, Administration, ”, New, University of Southern California’s Gould School of Law, Norfolk, Union Pacific, Federal Railroad Safety, Pacific, GlaxoSmithKline, Monsanto, Bayer, Parent Locations: Virginia, England, U.S, New York, Kirkland, East Palestine , Ohio, Louisiana, Atlanta, Vermont, Wise , Virginia, Wisconsin
☆ Merck accused of downplaying early evidence of drug’s brain impact
  + stars: | 2023-06-26 | by ( Robin Respaut Dan Levine | Robin Respaut | Dan Levine | ) www.reuters.com   time to read: +4 min
[1/6] Jan Gilpin poses with a bottle of the asthma and allergy drug Singulair, first prescribed to her son when he was three-years-old, at her home in Newton, Massachusetts, U.S., June 21, 2023. That team found in 2015 that the drug’s distribution into the brain was more significant than its label described. Lawsuits filed against Merck cite this 1996 patent as evidence of Merck’s knowledge of the drug’s potential brain impacts. Marschallinger and her colleagues in Austria came away with a different finding when they reviewed Merck’s original research and did some of their own. Marschallinger said it would have been logical for the FDA to require Merck to investigate the brain impacts more thoroughly once reports of mental-health problems emerged.
Persons: Jan Gilpin, Singulair, Brian Snyder, Merck, Julia Marschallinger, Marschallinger, ” Marschallinger, “ It’s, Robin Respaut, Dan Levine, Janet Roberts, Brian Thevenot Organizations: REUTERS, Brian Snyder Companies Merck, Co, FDA, Molecular Regenerative, Singulair, Merck, Thomson Locations: Newton , Massachusetts, U.S, Austria
0 next >>
Total: 2